A Phase 2 interventional study of mavacamten in Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 21st largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 2, and was the 6th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:
University of Manchester · Sites in United Kingdom
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University
Ages 18+
By country, each count listing its studies:
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 7 · Phase 4 4
First in 2014; this study’s year is marked. 4 started in 2018.
This study's enrollment of 13 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 75 across the 21 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb: 9 open now, 14 under way, 1 of them phase 3. Of 17 finished, 8 (47%) have results posted.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2018, is one of 4 in phase 2, and was the 6th registered.
Bristol-Myers Squibb’s Cardiomyopathy, Hypertrophic studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
Among Bristol-Myers Squibb’s 31 in Cardiomyopathy, Hypertrophic:
This tab as a report to print or save as PDF → With an account.
This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: mavacamten
mavacamten capsules
Also known as: MYK-461
Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: * Results in death * Is immediately life-threatening (places the participant at immediate risk of death from the event as it occurred) * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions * Results in a congenital abnormality or birth defect * Is an important medical event that may not result in death, be life- threatening, or require hospitalization, but may be considered an SAE when, based upon appropriate medical judgment, it may require medical or surgical intervention to prevent any of the outcomes listed above.
Time frame: From first dose to end of treatment + 56 days (Approximately an average of 240 Weeks)
Number of Participants Who Had Cardiovascular Death
Number of participants who had died due to cardiovascular reasons.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants Who Experienced Sudden Death
Number of participants who experienced sudden death
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants Who Were Hospitalized for Cardiovascular Reasons.
Number of participants who were hospitalized for cardiovascular reasons.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50%
Number of participants with heart failure due to systolic dysfunction, defined as asymptomatic LVEF \< 50%
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants With LVEF < 50% as Measured by Echocardiography.
Number of participants with LVEF \< 50% as measured by echocardiography.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants Who Were Experienced Myocardial Infarction
Number of participants who experienced myocardial infarction.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants With Ventricular Arrhythmias.
Types of Ventricular Arrhythmias measured in this endpoint will be: Ventricular Tachycardia Ventricular Fibrilation Ventricular Flutter
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants Who Experienced Syncope
Number of participants who experienced syncope. Syncope will be defined as participants who experienced dizziness or orthostatic hypotension.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants Who Experienced Seizures
Number of participants who were experienced seizures.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants Who Were Experienced Strokes
Number of participants who were experienced strokes.
Time frame: From first dose to end of study, (approximately 260 weeks)
Number of Participants With a Change in QT and QTcF Intervals.
Number of participants with a change in QTcF intervals. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/∛(RR/1000) RR = Respiration rate QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec
Time frame: From first dose to end of study, (approximately 260 weeks)
Post-exercise Left Ventricular Outflow Tract (LVOT) Gradient Over Time
Number of participants with changes of Post-exercise left ventricular outflow tract (LVOT) gradient over time
Time frame: At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252
Resting Left Ventricular Outflow Tract (LVOT) Gradient Over Time
Resting left ventricular outflow tract (LVOT) gradient over time
Time frame: At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252
Post Valsalva Left Ventricular Outflow Tract (LVOT) Gradient Over Time
Post Valsalva left ventricular outflow tract (LVOT) gradient over time
Time frame: At Baseline, Week 4, Week 48, Week 72, Week 156, Week 204 and Week 252
Participants With >= 1 NYHA Function Class Improvement
Participants with \>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Mean Change From Baseline in the Overall KCCQ PRO Score.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered 23-item questionnaire questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. Overall KCCQ Pro score is the average of all the domains, symptom frequency and symptom burden scores, and transformed to a single score which ranged from 0 (worst) to 100 (the best possible status), where the higher score reflected better health status.
Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Mean Change From Baseline in Serum NT-proBNP.
Mean change from baseline in Serum N-terminal pro B-type natriuretic peptide levels.
Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
Number of Participants Who Received Septal Reduction Therapy
Number of participants who received septal reduction therapy
Time frame: 252 weeks
Plasma Concentration of Mavacamen Overtime
Plasma concentration of Mavacamen overtime
Time frame: At Baseline, Week 4, Week 8, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 156, Week 180, Week 204, Week 228 and Week 252
| Milestone | Mavacamtem |
|---|---|
| Started | 13 |
| Completed | 11 |
| Not completed | 2 |
| Withdrew: Other reasons | 1 |
| Withdrew: Adverse event | 1 |
AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence at any dose that: * Results in death * Is immediately life-threatening (places the participant at immediate risk of death from the event as it occurred) * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions * Results in a congenital abnormality or birth defect * Is an important medical event that may not result in death, be life- threatening, or require hospitalization, but may be considered an SAE when, based upon appropriate medical judgment, it may require medical or surgical intervention to prevent any of the outcomes listed above.
| Participants | Mavacamtem |
|---|---|
| TEAEs | 13 |
| TESAEs | 5 |
Number of participants who had died due to cardiovascular reasons.
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Had Cardiovascular Death | 0 |
Number of participants who experienced sudden death
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Experienced Sudden Death | 0 |
Number of participants who were hospitalized for cardiovascular reasons.
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Were Hospitalized for Cardiovascular Reasons. | 1 |
Number of participants with heart failure due to systolic dysfunction, defined as asymptomatic LVEF \< 50%
| Participants | Mavacamtem |
|---|---|
| Number of Participants With Heart Failure Due to Systolic Dysfunction, Defined as Asymptomatic LVEF < 50% | 0 |
Number of participants with LVEF \< 50% as measured by echocardiography.
| Participants | Mavacamtem |
|---|---|
| Number of Participants With LVEF < 50% as Measured by Echocardiography. | 2 |
Number of participants who experienced myocardial infarction.
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Were Experienced Myocardial Infarction | 0 |
Types of Ventricular Arrhythmias measured in this endpoint will be: Ventricular Tachycardia Ventricular Fibrilation Ventricular Flutter
| Participants | Mavacamtem |
|---|---|
| Ventricular Tachycardia | 1 |
| Ventricular Fibrilation | 0 |
| Ventricular Flutter | 0 |
| Torsades De Pointe | 0 |
Number of participants who experienced syncope. Syncope will be defined as participants who experienced dizziness or orthostatic hypotension.
| Participants | Mavacamtem |
|---|---|
| Dizziness | 2 |
| Orthostatic Hypotension | 1 |
Number of participants who were experienced seizures.
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Experienced Seizures | 0 |
Number of participants who were experienced strokes.
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Were Experienced Strokes | 0 |
Number of participants with a change in QTcF intervals. QTcF: An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula. QTc = QT/∛(RR/1000) RR = Respiration rate QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec
| Participants | Mavacamtem |
|---|---|
| Post Baseline QTcF > 450msec | 7 |
| Post Baseline QTcF > 480msec | 1 |
| Post Baseline QTcF > 500msec | 1 |
| Change from Baseline QTcF > 30 msec | 2 |
| Change from Baseline QTcF > 60 msec | 1 |
Number of participants with changes of Post-exercise left ventricular outflow tract (LVOT) gradient over time
| Participants | Mavacamtem |
|---|---|
| Baseline — < 30 mmHg | 0 |
| Baseline — >= 30 mmHg to < 50 mmHg | 0 |
| Baseline — >= 50 mmHg | 13 |
| Week 4 — < 30 mmHg | 0 |
| Week 4 — >= 30 mmHg to < 50 mmHg | 3 |
| Week 4 — >= 50 mmHg | 10 |
| Week 48 — < 30 mmHg | 6 |
| Week 48 — >= 30 mmHg to < 50 mmHg | 3 |
| Week 48 — >= 50 mmHg | 2 |
| Week 72 — < 30 mmHg | 8 |
| Week 72 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 72 — >= 50 mmHg | 3 |
| Week 156 — < 30 mmHg | 10 |
| Week 156 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 156 — >= 50 mmHg | 2 |
| Week 204 — < 30 mmHg | 9 |
| Week 204 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 204 — >= 50 mmHg | 2 |
| Week 252 — < 30 mmHg | 9 |
| Week 252 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 252 — >= 50 mmHg | 2 |
Resting left ventricular outflow tract (LVOT) gradient over time
| Participants | Mavacamtem |
|---|---|
| Baseline — < 30 mmHg | 3 |
| Baseline — >= 30 mmHg to < 50 mmHg | 2 |
| Baseline — >= 50 mmHg | 8 |
| Week 4 — < 30 mmHg | 8 |
| Week 4 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 4 — >= 50 mmHg | 5 |
| Week 48 — < 30 mmHg | 11 |
| Week 48 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 48 — >= 50 mmHg | 0 |
| Week 72 — < 30 mmHg | 11 |
| Week 72 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 72 — >= 50 mmHg | 0 |
| Week 156 — < 30 mmHg | 11 |
| Week 156 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 156 — >= 50 mmHg | 0 |
| Week 204 — < 30 mmHg | 10 |
| Week 204 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 204 — >= 50 mmHg | 1 |
| Week 252 — < 30 mmHg | 11 |
| Week 252 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 252 — >= 50 mmHg | 0 |
Post Valsalva left ventricular outflow tract (LVOT) gradient over time
| Participants | Mavacamtem |
|---|---|
| Baseline — < 30 mmHg | 0 |
| Baseline — >= 30 mmHg to < 50 mmHg | 1 |
| Baseline — >= 50 mmHg | 11 |
| Week 4 — < 30 mmHg | 3 |
| Week 4 — >= 30 mmHg to < 50 mmHg | 2 |
| Week 4 — >= 50 mmHg | 8 |
| Week 48 — < 30 mmHg | 9 |
| Week 48 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 48 — >= 50 mmHg | 2 |
| Week 72 — < 30 mmHg | 9 |
| Week 72 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 72 — >= 50 mmHg | 1 |
| Week 156 — < 30 mmHg | 10 |
| Week 156 — >= 30 mmHg to < 50 mmHg | 1 |
| Week 156 — >= 50 mmHg | 1 |
| Week 204 — < 30 mmHg | 9 |
| Week 204 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 204 — >= 50 mmHg | 3 |
| Week 252 — < 30 mmHg | 10 |
| Week 252 — >= 30 mmHg to < 50 mmHg | 0 |
| Week 252 — >= 50 mmHg | 1 |
Participants with \>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
| Percentage of Participants | Mavacamtem |
|---|---|
| Change from baseline at week 4 | 15.4 (1.92 to 45.45) |
| Change from baseline at week 8 | 46.2 (19.22 to 74.87) |
| Change from baseline at week 24 | 76.9 (46.19 to 94.96) |
| Change from baseline at week 48 | 75.0 (42.81 to 94.51) |
| Change from baseline at week 72 | 90.9 (58.72 to 99.77) |
| Change from baseline at week 96 | 83.3 (51.59 to 97.91) |
| Change from baseline at week 120 | 91.7 (61.52 to 99.79) |
| Change from baseline at week 144 | 91.7 (61.52 to 99.79) |
| Change from baseline at week 156 | 91.7 (61.52 to 99.79) |
| Change from baseline at week 180 | 83.3 (51.59 to 97.91) |
| Change from baseline at week 204 | 83.3 (51.59 to 97.91) |
| Change from baseline at week 228 | 83.3 (51.59 to 97.91) |
| Change from baseline at week 252 | 90.9 (58.72 to 99.77) |
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered 23-item questionnaire questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. Overall KCCQ Pro score is the average of all the domains, symptom frequency and symptom burden scores, and transformed to a single score which ranged from 0 (worst) to 100 (the best possible status), where the higher score reflected better health status.
| Scores on a Scale | Mavacamtem |
|---|---|
| Change from baseline at week 4 | 5.809 ± 8.7200 |
| Change from baseline at week 8 | 12.304 ± 15.7392 |
| Change from baseline at week 24 | 16.931 ± 18.4502 |
| Change from baseline at week 48 | 16.345 ± 18.2986 |
| Change from baseline at week 72 | 18.600 ± 16.7875 |
| Change from baseline at week 96 | 16.162 ± 18.2376 |
| Change from baseline at week 120 | 18.142 ± 15.9249 |
| Change from baseline at week 144 | 17.860 ± 15.5829 |
| Change from baseline at week 156 | 18.750 ± 15.5701 |
| Change from baseline at week 180 | 16.674 ± 15.6328 |
| Change from baseline at week 204 | 19.661 ± 15.9783 |
| Change from baseline at week 228 | 91.122 ± 10.6882 |
| Change from baseline at week 252 | 89.489 ± 12.7977 |
Mean change from baseline in Serum N-terminal pro B-type natriuretic peptide levels.
| ng/L | Mavacamtem |
|---|---|
| Change from baseline at week 4 | -1017.4 ± 1540.78 |
| Change from baseline at week 8 | -1440.6 ± 2063.89 |
| Change from baseline at week 24 | -1512.8 ± 2242.40 |
| Change from baseline at week 48 | -1579.2 ± 2328.81 |
| Change from baseline at week 72 | -1708.4 ± 2448.93 |
| Change from baseline at week 96 | -1579.1 ± 2339.95 |
| Change from baseline at week 120 | -1692.7 ± 2426.02 |
| Change from baseline at week 144 | -1507.8 ± 2407.34 |
| Change from baseline at week 156 | -1673.5 ± 2460.82 |
| Change from baseline at week 180 | -1433.6 ± 2347.72 |
| Change from baseline at week 204 | -1568.7 ± 2400.63 |
| Change from baseline at week 228 | -1325.5 ± 2368.77 |
| Change from baseline at week 252 | -1681.5 ± 2409.67 |
Number of participants who received septal reduction therapy
| Participants | Mavacamtem |
|---|---|
| Number of Participants Who Received Septal Reduction Therapy | 0 |
Plasma concentration of Mavacamen overtime
| ng/mL | Mavacamtem |
|---|---|
| Week 4 | 166.51 ± 32.1 |
| Week 8 | 334.65 ± 21.5 |
| Week 24 | 396.18 ± 31.7 |
| Week 48 | 400.15 ± 35.1 |
| Week 72 | 407.27 ± 24.4 |
| Week 96 | 422.82 ± 29.3 |
| Week 120 | 399.17 ± 33.2 |
| Week 144 | 410.23 ± 42.8 |
| Week 156 | 400.02 ± 44.1 |
| Week 180 | 265.04 ± 57.9 |
| Week 204 | 376.25 ± 69.5 |
| Week 228 | 355.29 ± 72.3 |
| Week 252 | 334.57 ± 52.1 |
Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 56 days): Approximately 240 Weeks All-Cause mortality (From randomization to end of study): Approximately 260 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mavacamten | 0/13 (0%) | 5/13 (38.5%) | 13/13 (100%) |
| Event | Mavacamten |
|---|---|
| Mitral valve incompetenceCardiac disorders | 1/13 |
| Cholecystitis acuteHepatobiliary disorders | 1/13 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 1/13 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/13 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/13 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/13 |
| Lumbar radiculopathyNervous system disorders | 1/13 |
| Aortic stenosisVascular disorders | 1/13 |
| Event | Mavacamten |
|---|---|
| FatigueGeneral disorders | 5/13 |
| NasopharyngitisInfections and infestations | 5/13 |
| Upper respiratory tract infectionInfections and infestations | 5/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/13 |
| HypertensionVascular disorders | 4/13 |
| Dizziness posturalNervous system disorders | 3/13 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/13 |
| DiarrhoeaGastrointestinal disorders | 2/13 |
| FallInjury, poisoning and procedural complications | 2/13 |
| Drug level increasedInvestigations | 2/13 |
| Age, Continuous(Years) | Mavacamtem |
|---|---|
| Mean | 57.8 ± 13.3 |
| Sex: Female, Male(Participants) | Mavacamtem |
|---|---|
| Female | 4 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | Mavacamtem |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 13 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Mavacamtem |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Nov 2023, 66 months.
Results were first posted in Jan 2025, 1 year 2 months after primary completion.
Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 66 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →